Navigation Links
Gene therapy slows progression of fatal neurodegenerative disease in children
Date:5/13/2008

New Rochelle, NY, May 13, 2008Gene therapy to replace the faulty CLN2 gene, which causes a neurodegenerative disease that is fatal by age 8-12 years, was able to slow significantly the rate of neurologic decline in treated children, according to a paper published online ahead of print in the May 2008 issue (Vol. 19 No. 5) of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. The paper is available free online at www.liebertpub.com/hum

Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) is an autosomal recessive genetic disorder that causes degeneration of the central nervous system. It is a form of Batten disease, a group of lysosomal storage disease in which a lipofuscin-like material is not broken down and accumulates in neurons, causing cognitive impairment, visual failure, seizures, and progressive deterioration of motor function.

Ronald Crystal and colleagues from Weill Cornell Medical College (New York, NY), describe a study conducted in 10 children with LINCL who received gene therapy to replace the defective CLN2 gene via administration of human CLN2 carried in an adeno-associated virus (AAV). In the paper entitled Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis with CNS Administration of a Serotype 2 Adeno-associated virus expressing the CLN2 cDNA, the authors report that over an 18-month period, assessment using a neurologic rating scale demonstrated significant slowing of disease progression in the treated, compared to the untreated children. On the basis of these findings, the authors proposed that additional studies to assess the safety and efficacy of AAV-mediated gene therapy for LINCL be pursued.

Although the treatment was associated with some serious adverse events in some patients, these were not unequivocally attributable to the gene therapy vector.

This clinical trial is an important step toward the development of treatments for this group of underserved i
'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Page: 1 2

Related biology news :

1. UC Davis stem researchers demonstrate safety of gene therapy using adult stem cells
2. Cell-based therapy shows promise in patients with Parkinsons disease
3. Cancer immunotherapy shows long-term promise in lung cancer
4. Effective cancer immune therapy through order in the blood vessels
5. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
6. Biomarkers allow doctors to match therapy to patient
7. MU researcher links hormone replacement therapy to breast cancer
8. Potential new target for multiple sclerosis therapy
9. Umbilical cord blood cell therapy may reduce signs and symptoms of Alzheimers disease
10. Umbilical cord blood cell therapy in an animal model of Alzheimers disease
11. Tumor-targeting viral therapy slows neuroblastoma, malignant peripheral nerve sheath tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
(Date:3/12/2015)... -- The mascots of the Atlantic Coast Conference spent ... Forest Baptist Medical Center. They stopped by as part ... Basketball Tournament. Young patients enjoyed bonding with their favorite ... Brenner Children,s Hospital is the pediatric arm ... hospital in northwest North Carolina ...
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March 17, ... here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost & ... - http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies ... compete in several different markets and industries. This ... witnessing an uptrend. Join Frost ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... may not have traveled nearly as far as ... University of Alberta researchers Phil Bell and Eric ... have migrated during the winter season, their range ... their treks were shorter. Bell and Snively,s findings ...
... The medical literature is chock full of risk ... life tables, regressions, survival analyses, and confidence intervals. ... of the book Medical Statistics Made Easy , ... possible explanations of statistical tests and descriptions used throughout ...
... showing that American toads who pal around with gray ... to cause limb malformations has strong implications for the ... experiments showed that when the toad tadpoles were raised ... whose larvae burrow into tadpole limb regions and disrupt ...
Cached Biology News:Study of polar dinosaur migration questions whether dinosaurs were truly the first great migrators 2New book dissects statistics for doctors and medical students 2New CU-Boulder study shows diversity decreases chances of parasitic disease 2New CU-Boulder study shows diversity decreases chances of parasitic disease 3
(Date:3/31/2015)... YORK , March 31, 2015  PlasmaTech ... company advancing protein biologic therapies and oncology supportive ... partner, Hanmi Pharmaceutical Co., Ltd ("Hanmi") (KSE: 128940) ... country,s Ministry of Food and Drug Safety ("MFDS") ... for MuGard, its oncology supportive-care treatment for the ...
(Date:3/31/2015)... 2015 Today, Cryos International, the world’s ... their U.S. facilities and inventory from New York City ... experience, Cryos’ relocation is a reflection of their increasing ... Orlando was completed during the first weekend of spring, ... place on April 6. The new facility in the ...
(Date:3/30/2015)... 30, 2015 With recent advancements in ... the government, major companies are getting into the Solar ... future mandates for renewable energy production, many homeowners are ... Solara Power is a new solar distribution company in ... that allow qualifying homeowners to enjoy the benefits of ...
(Date:3/30/2015)... & Struggles (Nasdaq: HSII ), the premier provider of ... culture shaping worldwide, today  announced that John Mitchell ... and Life Sciences practice. As Global Practice Managing ... team of more than 80 partners, principals and associates in ... Asia serving clients in the biopharmaceutical, medical technology ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 2PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 3Cryos International Completes Groundbreaking Sperm Migration to Orlando, Florida 2Solara Power Announces Residential Solar Power with No Up-Front Fees 2Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2
... Calif., Dec. 5, 2011 OvaGene Oncology Inc., ... and commercialization of personalized gene-based diagnostics for gynecologic ... major Licensing and Collaboration Agreement with The Moffitt ... Comprehensive Cancer Center in Florida.  The agreement provides ...
... REDWOOD CITY, Calif., Dec. 5, 2011 Codexis, Inc. (Nasdaq: ... has been named Vice President and Chief Marketing Officer.  ... for the company,s corporate marketing and communications.  He will ... Officer. Mr. Bolsen is a widely recognized ...
... 2011  Immune Design Corp. announced today that Wayne ... new Chief Development Officer.  Dr. Gombotz brings a ... key leadership position at Immune Design.  He will ... therapeutic vaccine product candidates. (Logo: ...
Cached Biology Technology:OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response 2OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response 3Codexis Names Wes Bolsen VP and Chief Marketing Officer 2Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer 2
1M stock solution (238mg/ml)...
...
Request Info...
... ZMD.330. Immunogen: Synthetic peptide derived from ... and mouse protein kinase C zeta isoform ... and mouse PKCzeta protein. Recognizes PKCzeta ... cross-react with PKCiota/lambda. Reactivity: Mouse Rat ...
Biology Products: